Equity · Healthcare
KRYS
NASDAQKrystal Biotech (KRYS)
The line runs 313 USD on 3 August through 346 USD on 10 September, on a scale from 300 to 380. Days the market did not trade hold the previous close, flat.
- Market cap
- 10.2B USD
- P/E (TTM)
- 43.4
- Revenue, year to Dec 2025
- 389.1M USD
- EPS, diluted, year to Dec 2025
- 6.84 USD
- 52-week range
- 137.45 USD – 378.20 USD
- Avg volume
- 37.5K
as of Sep 10, 2026
Have Krystal Biotech (KRYS) insiders bought or sold shares recently?
In the 90 days to 1 Nov 2026, Krystal Biotech insiders reported 3 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 24 Feb 2026, show no open-market purchase.
Form 4, 90 days to 1 Nov 2026, newest reported trade 4 Sep 2026
Buys 0Sells 3Net sold $26.19MOther filings 1
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 04 Sep 2026 | Krishnan Krish SPresident and CEO | Sell | 25,000 | 9.0M USD |
| 04 Sep 2026 | Krishnan SumaPresident, R&D | Sell | 25,000 | 9.0M USD |
| 14 Aug 2026 | ROSSI DINO ADirector | Sell | 25,000 | 8.2M USD |
| Sold | 3 open-market sales | 75,000 | $26.19M |
1 other filing in the window: a grant, exercise, tax withholding or transfer, not a trade
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 14 Aug 2026 | ROSSI DINO ADirector | Gift | 3,691 |
Which funds hold Krystal Biotech (KRYS)?
6 of the 45 institutional funds we track reported a Krystal Biotech position for the quarter ended 30 Jun 2026 — a combined 61.2M USD; the latest of those filings landed 02 Sep 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Renaissance Technologies | Added | 59,680 | 22.2M USD | +521.7% |
| Bridgewater Associates | Held (±25%) | 54,489 | 20.3M USD | +17.5% |
| Fisher Asset Management | Held (±25%) | 27,676 | 10.3M USD | −0.4% |
| AQR Capital Management | Held (±25%) | 14,002 | 5.2M USD | −0.8% |
| Two Sigma Investments | New position | 6,084 | 2.3M USD | |
| Citadel Advisors | Held (±25%) | 2,725 | 1.0M USD | −0.0% |
| D. E. Shaw & Co. | Exited | |||
| Marshall Wace | Exited | |||
| Millennium Management | Exited | |||
| Tudor Investment Corp | Exited |
Have members of Congress traded Krystal Biotech (KRYS)?
The most recent congressional trade disclosed in Krystal Biotech is a purchase by Sara Jacobs (house, CA), dated 12 Dec 2022.
STOCK Act disclosures
| Traded | Member | Type | Amount | Filed after |
|---|---|---|---|---|
| 12 Dec 2022 | Sara Jacobshouse · Democrat–CA | Purchase | 1K USD–15K USD | 39 days |
What has been filed or recorded for Krystal Biotech (KRYS)?
The filings we hold for Krystal Biotech, newest first: 4 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 14 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 14 Oct 2026 | Fails to deliver | Shares failed to deliver | 562 shares | 180K USD notional · 0.002% of shares out |
| 09 Oct 2026 | Fails to deliver | Shares failed to deliver | 115 shares | 38K USD notional · <0.001% of shares out |
| 18 Sep 2026 | Fails to deliver | Shares failed to deliver | 10 shares | 3K USD notional · <0.001% of shares out |
| 17 Sep 2026 | Fails to deliver | Shares failed to deliver | 462 shares | 156K USD notional · 0.002% of shares out |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS 1.79 USD | Revenue $119M |
| 30 Jun 2026 | Financials | Total assets | 1.5B USD | at period end |
| 30 Jun 2026 | Financials | Total equity | 1.4B USD | at period end |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS 1.83 USD | Revenue $116M |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS 6.84 USD | Revenue $389M |
| 31 Dec 2025 | Financials | Revenue | 389.1M USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | 204.8M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | 6.84 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS 2.66 USD | Revenue $98M |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS 1.29 USD | Revenue $96M |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS 1.20 USD | Revenue $88M |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS 3.00 USD | Revenue $291M |
| 30 Sep 2024 | Quarterly earnings | Q3 2024 reported | EPS 0.91 USD | Revenue $84M |
Krystal Biotech (KRYS): frequently asked questions
What did Krystal Biotech shares close at?
Krystal Biotech closed at 346.00 USD on 10 Sep 2026, down 0.60% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Krystal Biotech’s market cap?
Krystal Biotech is worth 10.2B USD by market value as of 10 Sep 2026, which is the share price times the shares on issue from its SEC filings.
What is Krystal Biotech’s P/E ratio?
Krystal Biotech has a price-to-earnings ratio of 43.4, as of 10 Sep 2026: the share price divided by what the company earned per share over the last four reported quarters. A higher number means the market pays more for each dollar of earnings.
What is Krystal Biotech’s revenue?
Krystal Biotech reported revenue of 389.1M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have Krystal Biotech insiders bought or sold shares recently?
In the 90 days to 1 Nov 2026, Krystal Biotech insiders reported 3 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 24 Feb 2026, show no open-market purchase. A further 1 filing was a grant, award, gift or exercise rather than an open-market trade. See Insiders
Which funds own Krystal Biotech?
6 of the 45 funds we track reported a Krystal Biotech position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were Renaissance Technologies, Bridgewater Associates and Fisher Asset Management. See Funds
Have members of Congress traded Krystal Biotech?
Yes. 1 trade in Krystal Biotech appears in the congressional disclosures we hold: a purchase by Sara Jacobs (House, CA) dated 12 Dec 2022, filed 20 Jan 2023. Amounts are disclosed as ranges, and a filing can follow the trade by up to 45 days. See Congress
When did Krystal Biotech last report earnings?
Krystal Biotech last reported earnings on 30 Jun 2026 for Q2 2026, with EPS of 1.79 USD; no next date is announced in SEC filings yet. See Filings
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), most closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- House disclosuresU.S. House of Representatives financial disclosures
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Jun 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings